Do eosinophils play a role in allergic reactions?

Do Eosinophils Play a Role in Allergic Reactions?

Yes, eosinophils are central effector cells in allergic reactions, playing a critical role in both immediate and late-phase allergic responses through release of cytotoxic proteins, lipid mediators, and cytokines that drive tissue inflammation and damage.

Mechanism of Eosinophil Involvement in Allergic Reactions

Eosinophils function as key effector cells alongside mast cells and basophils in allergic inflammation 1. These granulocytes are recruited to tissues during allergic responses and contribute to pathology through multiple mechanisms:

Immediate and Late-Phase Responses

• Early phase: Eosinophils possess IgE receptors (FcεRII) and can undergo IgE-dependent activation and degranulation, directly participating in immediate-type allergic reactions 2
• Late phase: Eosinophils infiltrate tissues 4-8 hours after allergen exposure, becoming the predominant inflammatory cell in the late-phase response 3
• The bidirectional interaction between mast cells and eosinophils—termed the "allergic effector unit"—amplifies and perpetuates allergic inflammation through both cell-cell contact and released mediators 4

Th2-Mediated Recruitment and Activation

Allergic reactions are characterized by Th2 immune responses that specifically activate eosinophils 5:

• Cytokine drivers: IL-4, IL-5, and IL-13 are elevated in allergic tissues and promote eosinophil development, recruitment, and survival
• Chemotactic signals: Eotaxin-3 and other chemokines direct eosinophil migration to inflamed tissues
• Adhesion molecules: VCAM-1 and ICAM-1 facilitate eosinophil extravasation from blood vessels into tissues 6

Clinical Evidence Across Allergic Diseases

Respiratory Allergies

In allergic rhinitis and asthma, eosinophils are consistently present and correlate with disease severity 3, 6:

• Nasal eosinophilia correlates with nasal airflow obstruction and bronchial hyperresponsiveness 6
• Nasal allergen challenge triggers both local and bronchial eosinophilic inflammation, demonstrating systemic eosinophil activation 6
• 50-80% of patients with eosinophilic esophagitis have concurrent allergic rhinitis, asthma, or atopic dermatitis 5

Tissue-Specific Allergic Inflammation

In eosinophilic esophagitis (EoE), eosinophils are the defining pathologic feature 5:

• Peak eosinophil counts ≥15 per high-power field are diagnostic
• Eosinophil levels correlate with symptom severity and tissue damage
• Treatment response is monitored by reduction in tissue eosinophil counts
• Seasonal variations in esophageal eosinophil levels mirror aeroallergen exposure patterns 5

Pathologic Mechanisms

Eosinophils cause tissue damage through release of:

1. Cytotoxic granule proteins: Major basic protein, eosinophil cationic protein, eosinophil peroxidase, and eosinophil-derived neurotoxin damage epithelial cells 7
2. Lipid mediators: Cysteinyl leukotrienes and platelet-activating factor (PAF) amplify inflammation 8, 2
3. Cytokines: Perpetuate Th2 responses and recruit additional inflammatory cells 7
4. Reactive oxygen species: Superoxide generation contributes to oxidative tissue injury 8, 2

Therapeutic Implications

The central role of eosinophils in allergic reactions has led to targeted therapies:

• Anti-IL-5 agents (mepolizumab, benralizumab) deplete eosinophils and show efficacy in severe asthma and hypereosinophilic disorders 9
• Anti-IL-13 agents (dupilumab, cendakimab) reduce eosinophil recruitment and activation 9
• Corticosteroids reduce eosinophil counts and improve symptoms across allergic diseases 5

Important Caveats

• Peripheral blood eosinophilia (10-50% of adults, 20-100% of children with EoE) provides supportive but not diagnostic evidence of allergic disease 5
• Tissue eosinophilia is more clinically relevant than blood counts for assessing disease activity
• Concurrent atopic conditions can elevate eosinophil counts independent of the primary allergic process 5
• Anti-IL-5 therapy in asthma reduces eosinophils but may not always correlate with symptom improvement, suggesting eosinophils are necessary but not solely sufficient for all allergic manifestations 8

In clinical practice, recognize that eosinophils are essential mediators of allergic tissue damage, making them both biomarkers of allergic inflammation and therapeutic targets. Their presence in tissues confirms Th2-driven allergic pathology and guides treatment decisions toward anti-inflammatory and eosinophil-depleting strategies 10, 11.